Safety and efficacy of influenza vaccination in renal transplant recipients - Commentary

Nature Clinical Practice Nephrology

Volumn 4, Issue 7, 2008, Pages 358-359

  Zand, Martin S ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Adjuvant; Influenza; Renal transplant recipient; Vaccination

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BELATACEPT; CYCLOSPORIN A; INFLUENZA VACCINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; VIRUS ANTIBODY;

ACUTE GRAFT REJECTION; ANTIBODY TITER; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; NOTE; PRIORITY JOURNAL;

EID: 46249083469     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0830     Document Type: Note

References (7)

1. Scharpé J et al. (2008) Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant 8: 332-337
2. McKee AS et al. (2007) How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27: 687-690
3. Guy B (2007) The perfect mix: recent progress in adjuvant research. Nat Rev Microbiol 5: 505-517
4. Thornley TB et al. (2007) Type 1 IFN mediates cross-talk between innate and adaptive immunity that abrogates transplantation tolerance. J Immunol 179: 6620-6629
5. - naive human B cells. Blood 109: 1611-1619
6. EBPG Expert Group on Renal Transplantation (2002) European best practice guidelines for renal transplantation: section IV: long-term management of the transplant recipient: IV.11 paediatrics (specific problems). Nephrol Dial Transplant 17 (Suppl 4): S55-S58
7. [No authors listed] (2004) Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 4 (Suppl 10): S160-S163